Jazz pharmaceuticals plc JAZZ.US Overview Analysis
)JAZZ AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has received the highest rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
JAZZ Current Performance
-2.99%
Jazz pharmaceuticals plc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to JAZZ
- FTRE Fortrea holdings incValue -Trend 2Swing Trading 4Whale Interest 2Dividend 1See more
JAZZ Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.